Thrombolytic therapy. From myocardial to cerebral infarction

Italian Journal of Neurological Sciences

Volumn 17, Issue 1, 1996, Pages 5-21

  Candelise, L ^a   Roncaglioni, C ^b   Aritzu, E ^a   Ciccone, A ^a   Maggioni, A P ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

acute cerebral stroke; cerebral recanalization; myocardial infarction; thrombolytic therapy

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTERY OCCLUSION; BLEEDING; BLOOD CLOT LYSIS; BRAIN INFARCTION; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; HEART INFARCTION; HUMAN; HYPOTENSION; MORTALITY; REVIEW; STROKE;

ANIMALS; CEREBRAL INFARCTION; CEREBROVASCULAR DISORDERS; HUMANS; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;

EID: 0029867892     PISSN: 03920461     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01995705     Document Type: Review

References (134)

1. ABE T., TERASHI A., TOHGI H. et al.: Clinical efficacy of intravenous administration of SM-9527 (tPA) in cerebral thrombosis. Clin. Eval., 18: 36-69, 1990.
2. ANDERSON V., WILLERSON J.T. Thrombolysis in acute myocardial infarction. Curr. Concepts, 329, 10: 703-709, 1993.
3. ANGLO-SCANDINAVIAN STUDY OF EARLY THROMBOLYSIS (ASSET): Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet, ii: 525-530, 1988.
4. ARDISSINO D., BARBERIS P., DE SERVI S. et al.: Recombinant tissue-type plasminogen activator followed by heparin compared with heparin alone for refractory unstable angina pectoris. Am. J. Cardiol. 66: 910-914, 1990.
5. BAIRD A.E., DONNAN G.A., AUSTIN M.C., FITT G.J., MCKAY W.J.: HMPAO SPECT measures reperfusion after thrombolytic therapy in acute stroke. In: Del Zoppo G.J., Mori E., Hacke W. (Eds.): Thrombolytic therapy in acute ischemic stroke, Springer-Verlag Berlin Heidelberg, pp. 301-303, 1993.
6. BAMFORD J., SANDERCOCK P., DENNIS M., BURN J., WARLOW C.: A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86-2: incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J. Neurol. Neurosurg. Psychiatry, 53: 16-22, 1990.
7. BAR F., VERMEER F., VERHEUGT F., COL J. et al.: Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter, randomised, placebo-controlled, clinical trial with Anistreplase. Circulation, 86: 131-137, 1992.
8. BARON J.C.: Pathophysiology of acute cerebral ischemia: PET studies in humans. Cerebrovascular Dis 1 (suppl.): 22-31, 1991.
9. BEDNAR M.M., MC AULIFFET., RAYMOND S., GROSS C.: Tissue plasminogen activator reduces brain injury in a rabbit model of thromboembolic stroke. Stroke, 21: 1705-1709, 1990.
10. BENES V., ZABRAMSKI J.M., BOSTON M., PUCA A., SPETZLER R.F.: Effect of intra-arterial antifibrinolytic agents on autologous arterial emboli in the cerebral circulation of rabbits. Stroke, 21: 1594-1599, 1990.
11. BERG-DAMMER E., TOPPER R., MOBIUS E., NAHSER H.C., KUHNE D.: Local thrombolytic therapy of thromboembolic occlusion of the middle cerebral artery. In: Proceedings of the Second International Conference on Acute Stroke. Geneva, 1-2, p. 62, 1991 (abstract).
12. BILLER J., LOVE B.B., MARSH E.E. et al. Spontaneous improvement after acute ischemic stroke. A pilot study. Stroke, 21: 1008-1012, 1990.
13. BOUSCHERY R.: Fibrinolytische Behandlung der Hirnembolic mit Streptokinase. Med. Welt., 43: 2588, 1967.
14. BRAUNWALD E.: The open-artery theory is alive and well again. N. Engl. J. Med. Nov. 25: 1650-1652, 1993.
15. BROTT T.: Thrombolytic therapy for stroke. Cerebrovascular and brain metabolism reviews, 3: 91-113, 1991.
16. BROTT T.G., HALEY E.C., LEVY D.E. et al.: Urgent therapy for stroke. Part. I Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke, 23: 632-640, 1992.
17. BRUCKER A.B., POTUSCHAK H., LAICH E., TRENKLER J., BOHM-JURKOVIC H., DEISENHAMMER E.: Relation of thrombolytic reperfusion and of collateral circulation to outcome in patients suffering cerebral main artery occlusion. In Del Zoppo G.J., Mori E., Hacke W. (Eds.). Thrombolytic therapy in acute ischemic stroke II. Springer-Verlag Berlin Heidelberg, 288-291, 1993.
18. BRUCKMANN H., FERBERT A.: Putaminal hemorrhage after recanalization of an embolie MCA occlusion treated with tissue plasminogen activator. Neuroradiology, 31: 95-97, 1989.
19. BUTEUX G., JABAULT V., SUISSE A.: Local recombinant tissue plasminogen activator to clear cerebral arterythrombosis developing soon after surgery. Lancet, 12: 1143-1144, 1988.
20. CANDELISE L.: New treatments for acute ischemic stroke. In: Adams H.P. Jr. (Ed.), Handbook of Cerebrovascular Diseases. M. Dekker, pp. 415-432, 1993.
21. CARTER L.P., GUTHKELCH A.N., OROZCO J., TEMELTAS O.: Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model. Stroke, 23: 883-888, 1992.
22. CHAMBERLAIN D.A.: Unanswered questions in thrombolysis. Am. J. Cardiol. 63: 34A-40A, 1989.
23. CHESEBRO J.H., KNATTERUD G., ROBERTS R. et al.: Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circ. 6, 1: 142-154, 1987.
24. CICCONE A., CANDELISE L.: Brain hemorrhage after thrombolysis: a meta-analysis of animal stroke models (submitted for publication).
25. CLARK W., MADDEN K., LYDEN P.D., ZIVIN A.: Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke. 22: 872-876, 1991.
26. DE LEY G., WEYNE J., DEMEESTER G. et al.: Experimental thromboembolic stroke studied by positron emission tomography: immediate versus delayed reperfusion by fibrinolysis. J. Cereb. Blood Flow Metab., 8: 539-545, 1988.
27. DEL ZOPPO G.J., POECK K., PESSIN M.S. et al.: Recombinant tissue plasminogen activator in acute thrombotic and embolie stroke. Ann. Neurol. 32: 78-86, 1992.
28. DEL ZOPPO G.J., COPELAND B.R., ANDERCHEK K., HACHE W., KOZIOL J.A.: Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction. Stroke, 21: 596-601, 1990.
29. DEL ZOPPO G.J., COPELAND B.R., WALZ T.A., ZYROFF J., PLOW E.F., HARKER L.A.: The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke, 17: 638-643, 1986.
30. DEL ZOPPO G.J., FERBERT A., OTIS S. et al.: Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke, 19: 307-313, 1988.
31. DEL ZOPPO G.J., PESSIN M., MORI E., HACKE W.: Thrombolytic intervention in acute thrombotic and embolic stroke. Seminars in Neurology, Vol. II; 4: 368-384, 1991.
32. DEL ZOPPO G.J., POECK K., PESSIN M.S. et al.: Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann. Neurol. 32: 78-86, 1992.
33. DONNAN G.A., DAVIS S.M., CHAMBERS B.R. et al.: Trials of streptokinase in severe acute ischaemic stroke (letter). Lancet, i, 345: 578-579, 1995.
34. ECGS (European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction): Streptokinase in acute myocardial infarction. N. Engl. J. Med. 301: 797-802, 1979.
35. EMERAS (Estudio Multicéntrico Estreptoquinasa Republicas de America del Sud) Collaborative Group: Randomised trial of late thrombolysis in patients with suspected acute mvocardial infarction. Lancet, 342: 767-772, 1993.
36. FALK E.: Coronary thrombosis: pathogenesis and clinical manifestations. Am. J. Cardiol. 68: 288-358, 1991.
37. FIESCHI C., ARGENTINO C., LENZI G.L. et al.: Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J. Neurol. Sci. 91: 311-322, 1989.
38. FORESTI A., ABROSINI F., GENTILE G., REPETTO S., LOTTO A.: Thrombolytic therapy in unstable angina: effects of short term high dose intravenous urokinase. Thromb. Haem., 58: 63, 1987 (abstract).
39. FREEMAN M.R. et al.: Thrombolysis in unstable angina: randomised double-blind trial of tPA and placebo. Circulation, 85: 150-157, 1992.
40. FRINK R.J., OSTRACH L.H.: Streptokinase in the treatment of an acute cerebral embolus. A case report. Angiology, 41: 66-69, 1990.
41. FTT Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet, 343: 311-322, 1994.
42. FUJIWARA H., ONODERA T., TANAKA M. et al.: A clinicopathologic study of patients with hemorrhagic myocardial infarction treated with selective coronary thrombolysis with urokinase. Circulation, 4: 749-757, 1986.
43. GOLD H.K., JOHNS J.A., LEINBACH R.C. et al.: A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris. Circulation, 75: 1192-1199, 1987.
44. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-2: a factorial randomised trial of alteplase versus Streptokinase and heparin versus no heparin among 12,490 patients with acute mvocardial infarction. Lancet, 336: 65-71, 1990.
45. Gruppo Italiano per lo Studio della Streptokinasi nell'Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet, i: 397-402, 1986.
46. GUERCI A.D., GERSTENBLITH G., BRINKER J.A., et al.: A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N. Engl. J. Med. 317: 1613-1618, 1987.
47. HACKE W., ZEUMRR H., FERBERT A., BRUCKMANN H., DEL ZOPPO G.J.: Intra-arterial thrombolytic therapy improves outcome in patients with acute vertehro-basilar occlusive disease. Stroke, 19: 1216-1222, 1988.
48. HACKE W.: Thrombolysis stroke and embolus type. In: Del Zoppo G.J., Mori E., Hacke W. (Eds.) Thrombolytic Therapy in Acute Ischemic Stroke II. Springer-Verlag, pp. 153-159, 1993.
49. HALEY B.C., BROTT T.G., SHEPPARD G.L. et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke, 24: 1000-1004, 1993.
50. HALEY E.C., LEVY D.E., BROTT T.G., et al.: urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke, 23: 641-645, 1992.
51. HALL G.H.: Bolus Streptokinase after mvocardial infarction. Lancet ii: 96-97, 1987.
52. HENDERSCHEÉ D., LIMBURG M., HIJDRA A., KOSTER P.A.: Recombinant tissue plasminogen activator in two patients with basilar artery occlusion. J. Neurol. Neurosurg Psychiatry, 54: 71-73, 1991.
53. HENNERICI M., HACKE W., VON KUMMER R., HORNIG C., ZANGEMEISTER W.: Intravenous tissue plasminogen activator for the treatment of acute thromboembolic ischemia. Cerebrovasc. Dis. 1(suppl. 1): 124-128, 1991.
54. HENZE T.H.: Lysis of basilar artery occlusion with tissut plasminogen activator. Lancet, ii, 12: 1391, 1987.
55. HOMMEL M., BOISSEL J.P., CORNU C. et al.: Terminatior of trial of streptokinase in severe acute ischaemic strokt (letter). Lancet, 345: 57, 1995.
56. HOSSMANN K.A.: Viability thresholds and the penumbn, of focal ischemia. Ann. Neurol. 36: 557-565, 1994.
57. ISIS (International Studies of Infarct Survival) Pilot Study Investigators: Randomized factorial trial of high-dost intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur. Heart. J., 8: 634-642, 1987.
58. ISIS 2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute mvocardial infarction: ISIS-2. Lancet, ii: 349-360, 1988.
59. JAEGERE P.P. DE, ARNOLD A.A., BALK A.H., SIMOONS M.L.: Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J. Am. Coll. Cardiol. 19: 289-294, 1992.
60. JAFAR J.J., TAN W.S., CROWELL R.M.: Tissue plasminogen activator thrombolysis of a middle cerebral artery embolus in a patient with an arteriovenous malformation. J. Neurosurg. 74: 808-812, 1991.
61. KARISSON J.E., BERGLUND U., BJOKHOLM A. et al.: Thrombolysis with recombinant human tissue type plasminogen activator during instability in coronary heart disease-effect on myocardial ischaemia and need for coronary revascularisation (TRIG study) (In press).
62. KARNIK R., STELZER P., SLANY J.: Transcranial doppler sonography monitoring of local intra-arterial thrombolysis in acute occlusion of the middle cereral artery. Stroke, 23: 284-287, 1992.
63. KASE C.S., PESSIN M.S., ZIVIN J.A. et al.: Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. Am. J. Med. 4: 384-390, 1992.
64. KASSMEYER H., WIDOCK W.: Thrombolyse bei Verschluss der Arteria Carotis Interna. Med-Welt, 31: 1737, 1965.
65. KENNEDY J.W., MARTIN G.V., DAVIS K.B. et al.: The Western Washington intravenous streptokinase in acute mvocardial infarction randomized trial. Circulation, 77: 345-352, 1988.
66. KITTNER S.J., SHARKNESS C.M., SLOAN M.A. et al.: Infarcts with a cardiac source of embolism in the NINDS Stroke Data Bank: Neurologic examination. Neurology, 42: 299-302, 1992.
67. KOUDSTAAL P.J., STIBBE J., VERMEULEN M.: Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke. Br. Med. J. 297: 1571-1574, 1988.
68. LATE Study Group: Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet, 342: 759-766, 1993.
69. LAU J., ANTMAN E.M., JEMENEZ-SILVA J., KUPELNICK B., MOSTELLER F., CHALMERS T.C.: Cumulative meta-analysis of therapeutic trials for myocardial infarction. N. Engl. J. Med. 327: 248-254, 1992.
70. LINCOFF A.M., TOPOL E.J.: Illusion of reperfusion - Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation, 87: 1792-1805, 1993.
71. LYDEN P.D., MADDEN K.P., CLARK W.M., SASSE K.C., ZIVIN J.A.: Incidence of cerebral hemorrhage after amifibronolytic treatment for embolic stroke in rabbits. Stroke, 21: 1589-1593, 1990.
72. LYDEN P.D., ZIVIN J.A., CLARK W.A. et al.: Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology, 39: 703-708, 1989.
73. [731 LYDEN P.D., ZIVIN J.A.: Hemorrhage transformation after cerebral ischemia: mechanism and incidence. Cerebrovasc. Brain Metab. Reviews, 5: 1-16, 1993.
74. MAGGIONI A.P., FRANZOSI M.G., SARTORO E., et al.: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and the International Study Group: The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombolytic treatment. N. Engl. J. Med. 327: 1-6, 1992.
75. MAGNANI B. for the PAIMS Investigators: Plasminogen Activator Italian Multicenter Study (PAIMS): Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. J. Am. Coll. Cardiol. 13: 19-26, 1989.
76. MAISA D., THERON J., PELOUZE G.A., et al.: Local fibrinolytic therapy in ischemic carotid pathology. Ann. Vasc. Surg. 2: 205-214, 1988.
77. MALINOVSKY N.N., KOZLOW V.A.: Embolism of the cerebral arteries. In: Malinovsky N.N., Kozlow V.A. (Eds.), Anticoagulant and Thrombolytic Therapy in Surgery. St. Luis, CV Mosby Company, pp. 239-250, 1979.
78. MARCHAL G., SERRATI C., RIOUX P. et al.: PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome. Lancet, 341: 925-927, 1993.
79. MARDER V.J.: Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. Am. J. Med. 83 (2A): 15-19, 1987.
80. MEYER G.S., GILROY J., BARNHART M.I. et al.: Anticoagulants plus streptokinase therapy in progressive stroke. JAMA, 189: 373, 1964.
81. MINEMATSU K., KAMAGUCHI T., OMAE R.: "Spectacular shrinking deficit": Rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology, 42: 157-162, 1992.
82. MOBIUS E., BERG-DAMMER E., KUHNE D., NAHSER H.C.: Local thrombolytic therapy in acute basilar artery occlusion: experience with 18 patients. In: Hacke W., Del Zoppo G.J., Hirschberg (Eds.), Thrombolvtic Therapy in Acute Ischemic Stroke. Berlin Heidelberg, Springer Verlag, pp. 213-215, 1991.
83. MORI E., YONEDA Y., TABUCHI M. et al.: Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology, 42: 976:998, 1992.
84. National Heart Foundation of Australia Coronary Thrombolysis Group: Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet, i: 203-207, 1988.
85. NENCI G.G., GRESELE P., TARAMELLI M., AGNELLI G., SIGNORINI E.: Thrombolytic therapy for thromboembolism of the vertebro-basilar artery. Angiology, 34: 561-571, 1983.
86. O'ROURKE M., BARON D., KEOGH A. et al.: Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circ. 77: 1311-1315, 1988.
87. OKADA Y., SADOSHIMA S., FUJISCHIMA M.: Thrombolytic therapy for acute cerebral embolism: its efficacy and the incidence of hemorrhagic transformation. J. Neurol. 238: 121, 1991.
88. OKADA Y., SADOSHIMA S., NAKANE H., UTSUNOMIYA H., FUJISHIMA M.: Early computed tomographic findings for thrombohtic therapy in patients with acute brain embolism. Stroke, 23: 20-23, 1992.
89. OLSON H.G., BUTMAN S.M., PITERS K.M. et al.: A randomized controlled trial of intravenous streptokinase in evolving acute mvocardial infarction. Am. Heart. J, 11: 1021-1029, 1986.
90. OTOMO E., TOGHI H., HIRAI S. et al.: Clinical efficacy of AK-124 (tissue plasminogen activator) in the treatment of cerebral thrombosis: study by means of multicenter double blind comparison with urokinase. Uakuri To Chiryo, 16: 3775-3821, 1988.
91. OVERGAARD K., SPERLING B., BOYSEN G. et al.: Thrombolytic therapy in acute ischemic stroke: A Danish pilot study. Stroke, 24: 1439-1446, 1993.
92. PHILLIPS D.A., FISHER M., DAVIS M.A., SMITH T.W., PANG R.H.L.: Delayed treatment with a tPA analogue and streptokinase in a rabbit embolic stroke model. Stroke, 21: 602-605, 1990.
93. [93[ PHILLIPS D.A., FISHER M., SMITH T.W., DAVIS M.A., PANG R.H.L.: The effects of a new tissue plasminogen activator analogue, Fb-Fb-CF, on cerebral reperfiision in a rabbit embolie stroke model. Ann. Neurol. 25: 281-285, 1989.
94. Primi Trial Study Group: Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute mvocardial infarction. Lancet, i: 863-869, 1989.
95. RINGELSTEIN E.B., BINIEK R., WEILLER C., AMMELING B., NOLTE P.N., THRON A: Type and extent of hemispheric brain infarctions and clinical outcome in early and delaved middle cerebral artery recanalization. Neurology, 42: 289-298, 1992.
96. RINGELSTEIN E.B., OTIS S.M., SPAAR-KAHLSCHEUER B., NIGGEMEYER E.: Transcranial Doppler sonography. Anatomical landmarks and normal velocity values. Ultra-sound Med. Biol. 16: 745-761, 1990.
97. ROBERTS M.J.D. et al.: Thrombolytic therapy for unstable angina - a double blind placebo-controlled trial with alteplase. Eur. Heart J., 12: 134, 1991 (abstract).
98. SABIA P.J., POWERS E.R., RAGOSTA M., SAREMBOCK I.J., BURWELL L.R., KAUL S.: An association between collateral blood flow and mvocardial viability in patients with recent mvocardial infarction. N. Engl. J. Med., 327: 1825-1831, 1992.
99. SANSA M., CEMIGLIARO C., CAMPI A., SIMONETTI I.: Effects of urokinase and heparin on minimal cross-sectional area of the culprit narrowing in unstable angina pectoris. Am. J. Cardiol., 68: 451-456, 1991.
100. [100[ SARAN R.K., BHANDARI K., NARAIN V.S. et al.: Intravenous streptokinase in the management of a subset of patients with unstable angina: a randomised controlled trial. Int. J. Cardiol. 28: 209-213, 1990.
101. SIMOONS M.L., MAGGIONI A.P., KNATTERUD G. et al.: Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet, 342: 1523-28, 1993.
102. SLIVKA A., PULSINELLI W.: Hemorrhagic complications of thrombolvtic therapv in experimental stroke. Stroke, 18: 1148-1156, 1987.
103. TERASHI A., HOBAYASHI Y., KATAYAMA Y., INAMURA K., KAZAMA M., ABE T.: Clinical effects and basic studies of thrombolvtic therapy on cerebral thrombosis. Semin Thromb Hemost, 16: 236-241, 1990.
104. The GUSTO investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329: 673-682, 1993.
105. THE INTERNATIONAL STUDY GROUP: In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparing. Lancet, 336: 71-75, 1990.
106. The ISAM Study Group: A prospective trial of intravenous streptokinase in acute mvocardial infarction (ISAM): mortality, morbidity and infart size at 21 days. N. Engl. J. Med. 314: 1465-1471, 1986.
107. The Thrombolysis Early in Acute Heart Attack Trial Study Group: Very early thrombolytic therapy in suspected acute myocardial infarction. Am. J. Cardiol., 65: 401-407, 1990.
108. THERON J., COURTEOUX P., CASASCO A. et al.: Local intraarterial fibrinolysis in the carotid territory. A J N R. 10: 753-765, 1989.
109. THIRD INTERNATIONAL STUDY OF INFARCT SURVIVAL. COLLABORATIVE GROUP: ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin alone among 41,299 cases of suspected acute mvocardial infarction. Lancet, 339: 753-770, 1992.
110. TIMI-3 trial. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non Q-wave myocardial infarction. Circulation, 89: 1545-1556, 1994.
111. TOPOL E.J., MORRIS D.C., SMALLING R.W. et al.: A multicenter randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute mvocardial infarction. J. Am. Coll. Cardiol., 9: 1205-1213, 1987.
112. TOPOL E.J., NICKLAS J.M., KANDER N.H. et al.: Coronary revascularization unstable angina pectoris: results of randomized double-blind placebo-controlled trial. Am. J. Cardiol. 62: 368-371, 1988.
113. TURRIN M., MARTINELLI S., GRAZIOLI E.: Fibrinolytic therapy in acute ischemic stroke: description of a case of carotid thrombolysis with rt-PA intravenous infusion. J. Neurol., 238: 126, 1991 (abstract).
114. VAN DE WERF F., ARNOLD A.E.R. for the European Cooperative Study Group for recombinant tissue-type plasminogen activator: Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute mvocardial infarction. Br. Med. J. 297: 1374-1379, 1988.
115. VAN DER BRAND M., VAN ZIJL A., GEUSKENS R., DE FHYTER P.J., SERRUYS P.W., SIMOONS M.: A randomised double-blind placebo controlled trial in patients with refractory unstable angina and subsequent angioplasty. European Heart Journal, 12: 1208-1214, 1991.
116. VERSTRAETE M., BERNARD R., BORY M. et al.: Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet, i: 842-847, 1985.
117. VERSTRAETE M., BLEIFELD W., BROWER R.W. et al.: Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute mvocardial infarction. Lancet, ii: 965-969, 1985.
118. VON BELZ G.G.: Fibrinolytische Therapie. Erfahrungsbefieht uber fung jahre. Munch Med. Wschr, 111: 2357, 1969.
119. VON KUMMER R., HACKE W.: Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke, 23: 646-652, 1992.
120. VON STRICKER E., SCHMUTZLER R.: Erfolgreiche thrombolyse eines arteriellen cerebralen Gefa-Bverschlusses. Schw Med. Woch, 18: 615-617, 1964.
121. WARDLAW J.M., WARLOW C.P.: Thrombolysis in acute ischemic stroke: Does it work? Stroke, 23: 1826-1839, 1992.
122. WHITE H.D., MORRIS R.M., BROWN M.A. et al.: Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N. Engl. J. Med. 317: 850-855, 1987.
123. WHITE H.D., RIVERS J.T., MASLOWSKI A.M. et al.: Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N. Engl. J. Med. 320: 817-821, 1989.
124. WILDEMANN B., HUTSCHENREUTER M., VON KUMMER R.: Infusion of recombinant tissue plasminogen activator for treatment of basilar artery occlusion. Stroke, 21, 10: 1513-1514, 1990.
125. WILLIAMS D.O., TOPOL E.J., CLAIFF R.M. et al.: Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled randomized trial. Circulation, 82: 376-383, 1990.
126. YAMAGUCHI T., HAYAKAWA T., KIKUCHI H., ABE T.: Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In Hacke W., Del Zoppo G.J., Hirschberg (Eds.) Thrombolytic Therapy in Acute Ischemic Stroke. Springer-Verlag Berlin Heidelberg, pp. 168-171, 1991.
127. YAMAGUCHI T., HAYAKAWA T., KIKUCHI H., ABE T.: Thrombolytic therapy in embolie and thrombotic cerebral infarction: a cooperative study. In: Hacke W., Del Zoppo G.J., Hirschberg (eds.) Thrombolytic Therapy in Acute Ischemic Stroke. Springer-Verlag Berlin Heidelberg, pp. 172-174, 1991.
128. YAMAGUCHI T., HAYAKAWA T., KIKUCHI H. for the Japanese Thrombolysis Study Group: Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolie stroke. Cerebrovasc. Dis. 3: 269-272, 1993.
129. YUSUF S., COLLINS R., PETO R. et al.: Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effect from 33 randomized controlled trials. Eur. Heart. J. 6: 556-585, 1985.
130. ZEUMER H., RINGELSTEIN E.B., KASSEL M., POECK K.: Lokale Fibrinolysetherapie bei sub totaler Stenose der a. cerebri media. Dtsch Med. Wschr., 108: 1103-1105, 1983.
131. ZEUMER H., HACKE W., KOLMANN H.L., POECK K.: Lokale Fibrinolysetherapia bei basilaris-Thrombose. Dtsch Med. Wschr, 107: 728-731, 1982.
132. ZEUMER H., HACKE W., RINGELSTEIN E.B.: Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease. AJNR, 4: 401-404, 1983.
133. ZEUMER H.: Vascular recanalizing techniques in interventional neuroradiology. J. Neurol. 231: 287-294, 1985.
134. ZIVIN J.A., FISHER M., DE GIROLAMI U., HEMENWAY C.C., STASHAK J.A.: Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science, 230: 1289-1292, 1985.